Whats new

Whats new.

Bell Potter - Lung cancer Phase 1 trial: Strong data update; Maintain Buy, A$0.70 PT (Analyst: Thomas Wakim)

November 14th 2024

For a copy of this research report please contact your Bell Potter advisor